The Promising Company OSE Pharma launches an IPO
Created in 2012 by Emile Loria and Dominique Costantini, OSE Pharma is a European cancer…
As one of the leading causes of death worldwide, cancer receives great focus from the life sciences industry. Indeed, it’s the largest therapeutic focus area for biotech and pharma companies, which are working on a large number of therapeutic approaches, including small molecules, T cell therapies, and antibody therapies.
Global cancer drug sales are estimated to reach €221B by 2024. The top 10 blockbuster drugs are sold by big pharma companies, like Roche, Merck, AbbVie, and Bristol-Myers Squibb. Examples of blockbusters include Keytruda, Rituxan, and Herceptin.
Biotech companies are doing a fair bit of the work as well. Read on to keep up to date with the latest oncology research, discoveries, and market developments.
A Guide to Current Therapies in Immuno-Oncology
From a rich history to a growing number of therapies, the immuno-oncology landscape has changed rapidly over the last decade. In this report, we look into its past, discuss present therapeutic approaches, and provide an outlook into its future.
Go to ReportCreated in 2012 by Emile Loria and Dominique Costantini, OSE Pharma is a European cancer…
MorphoSys AG and Emergent BioSolutions will initiate a Phase I clinical study to evaluate the…
Completes transactions with GSK including: acquisition of GSK oncology portfolio, creation of Consumer Healthcare joint…
Bristol-Myers Squibb signs an exclusive agreement with Bavarian Nordic for PROSTVAC, a prostate-specific antigen-targeting cancer…
Researchers in Barcelona have developed a shuttle to transport drugs into the brain, running through the…
Tumor microenvironment, including tumor-associated macrophages, plays a key role in controlling tumor progression and response…
Nanobiotix is an oncology focused nanomedicine company developing an innovative nanoparticle technology. Their NanoXray technology…
Curie-Cancer, the part responsible for developing Institut Curie’s industry partnership activities, and GamaMabs Pharma, a company specialized in…
iTeos Therapeutics SA enters in a strategic collaboration with Pfizer Inc where iTeos will license to…
Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer…
Janssen's Imbruvica (ibrutinib), the once-daily oral Bruton's tyrosine kinase (BTK) inhibitor, has been approved in Europe…
A novel concept of fully personalized therapeutic cancer vaccines, called Glioma Actively Personalized VAccine Consortium…